Clinical Catch-Up: March 29-April 2,

The Cancer Research Institute (CRI) and RevImmune dosed the first patient in a new Phase II trial of interleukin-7 (IL-7) in cancer patients with COVID- …, The Cancer Research Institute (CRI) and RevImmune dosed the first patient in a new Phase II trial of interleukin-7 (IL-7) in cancer patients with COVID- …, Read More

Scroll to Top